SX
SXTC.US China SXT Pharmaceuticals Inc
- Market cap
- USD 296K
- P/E
- -
- P/B
- 0.01x
- ROE
- 2.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is SXTC.US undervalued?
Graham numberThe Graham number of China SXT Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China SXT Pharmaceuticals Inc fundamental analysis
No fundamental analysis for China SXT Pharmaceuticals Inc yet.
China SXT Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKui…
Full company profileChina SXT Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China SXT Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.88M | 7.02M | 7.01M | 5.16M | 4.78M | 2.60M | 1.97M | 1.93M | 1.74M | 1.07M | 4.79M |
| Gross Profit | 2.31M | 3.40M | 4.61M | 2.70M | 2.84M | 1.25M | 426K | 554K | 367K | 183K | 3.34M |
| Operating Income | 1.60M | 1.63M | 1.77M | -1.34M | -2.20M | -5.19M | -5.61M | -2.52M | -2.68M | -7.12M | -3.14M |
| EBITDA | 1.70M | 1.76M | 1.98M | -1.01M | -1.85M | -5.05M | -5.21M | -2.35M | -2.57M | -6.98M | -2.69M |
| Net Income | 1.19M | 1.19M | 1.54M | -10.3M | -2.75M | -5.74M | -5.93M | -3.10M | -3.30M | -6.21M | 655K |
| EPS | 9,959 | 9,980 | 14,944 | -82,967 | -9,542 | -13,789 | -2,223 | -357 | -818 | -913 | 112 |
| Balance Sheet | |||||||||||
| Total Assets | 5.43M | 7.66M | 17.5M | 21.7M | 34.5M | 33.5M | 29.6M | 23.1M | 21.7M | 34.8M | 34.8M |
| Total Liabilities | 3.58M | 4.37M | 6.36M | 12.3M | 18.6M | 17.1M | 14.9M | 9.20M | 6.22M | 5.05M | 5.05M |
| Shareholders' Equity | 1.85M | 3.29M | 11.1M | 9.40M | 16.0M | 16.4M | 14.7M | 13.9M | 15.4M | 29.7M | 29.7M |
| Cash & Short-term Investments | 65.6K | 560K | 9.13M | 7.29M | 13.3M | 15.5M | 17.4M | 12.1M | 18.1M | 28.2M | 28.2M |
| Total Debt | 302K | 385K | 2.79M | 6.72M | 43.4K | 10.7M | 3.76M | 2.65M | 984K | 1.12M | 1.12M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 293K | 1.92M | 239K | 934K | -1.32M | -2.37M | -80.8K | -1.93M | -2.35M | -4.02M | -9.06M |
| Capital Expenditure | 186K | 1.05M | 610K | 407K | 93.0K | 62.5K | 70.7K | 7.06K | 2.02K | 4.00 | 0.00 |
| Free Cash Flow | 107K | 869K | -371K | 528K | -1.41M | -2.44M | -151K | -1.94M | -2.35M | -4.02M | -9.06M |
| Ratios | |||||||||||
| ROE | 64.0% | 36.1% | 13.9% | -109.4% | -17.2% | -34.9% | -40.4% | -22.2% | -21.4% | -20.9% | 2.2% |
| ROA | 21.8% | 15.5% | 8.8% | -47.4% | -8.0% | -17.1% | -20.1% | -13.4% | -15.2% | -17.9% | 1.9% |
| Net Profit Margin | 24.3% | 16.9% | 22.0% | -199.3% | -57.5% | -220.4% | -301.0% | -160.7% | -189.8% | -578.5% | 13.7% |
| Debt to Equity | 0.16x | 0.12x | 0.25x | 0.72x | 0.00x | 0.65x | 0.26x | 0.19x | 0.06x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China SXT Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 2.38M | 23,135 | 154.8% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on Oct 26, 2026.
Who owns China SXT Pharmaceuticals Inc
- Insiders 2.26%
- Institutions 0.03%
- Public & others 97.71%
- Shares outstanding 104K
- Free float 268K
Top funds holding SXTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 356.00 | 0.00% | 0.00% | May 2026 |
Top institutions holding SXTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Royal Bank of Canada | 13.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | +100.00% | Jun 2026 |
| UBS Group AG | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Sabby Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
China SXT Pharmaceuticals Inc company profile
- Company name
- China SXT Pharmaceuticals Inc
- Ticker
- SXTC.US
- ISIN
- VGG2161P1320
- Exchange
- USA Stocks
- Listed since
- Jan 4, 2019
- Sector
- Healthcare
- Industry
- Personal Care Products
- Employees
- 56
- Fiscal year end
- March
- Address
- 178 Taidong Road North, Taizhou, China, 225300
- Phone
- 86 523 8629 8290
- Website
- sxtchina.com
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
China SXT Pharmaceuticals Inc management
4- Mr. Feng ZhouChairman of the Board & Co-CEO · born 1992
- Mr. Sze Beng LimCo-Chief Executive Officer · born 1977
- Mr. Xiaodong PanChief Financial Officer · born 1977
- Mr. Jun ZhengExecutive Director · born 1976